Jubilant Therapeutics Inc. to Present at Credit Suisse and Jefferies Investor Conferences
04 November 2022 | Friday | News
-Jubilant Therapeutics Inc., a clinical-stage biopharmaceutical company developing precision oral drugs with an improved therapeutic index for genetically defined patients with cancer and autoimmune diseases, today announced thatSyed Kazmi , Chief Executive Officer, will give a presentation on the current course of business and meet institutional investors at the following conferences in November 2022:
|
Event: |
Credit Suisse 31st Annual Health Conference, Ranchos Palos Verde, California |
|
Date: |
Monday, November 7 to Thursday, November 10, 2022 |
|
Participant: |
Syed Kazmi, Chief Executive Officer, Jubilant Therapeutics Inc. |
|
Time: |
2:35 p.m. to 3:05 p.m. PST (5:35 p.m. to 6:05 p.m. EST) on Wednesday,November 9 |
|
Event: |
Jefferies London Healthcare Conference, London |
|
Date: |
Tuesday, November 15 to Thursday, November 17 |
|
Participant: |
Syed Kazmi, Chief Executive Officer, Jubilant Therapeutics Inc. |
|
Time: |
8:35 a.m. GMT (3:35 a.m. EST) on Wednesday,November 16 |
Most Read
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
